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1. Introduction
Acute Myocardial Infarction (AMI) is both a common and deadly type of cardiac event in
the United States. Although the age-adjusted hospitalization rate for AMI and its in-hospital
case fatality rates have both declined since the mid-1990s, there were still 634,000 inpatient
admissions in 2009 for which AMI was listed as the primary diagnosis [1, 2]. Moreover,
Americans suffered an estimated 610,000 first-time AMIs and 325,000 recurrent attacks, and
133,958 deaths in 2008 [2]. Because the declines in hospitalization and in-hospital mortality
rates have been associated with more aggressive therapeutic interventions [1], it is impor‐
tant to evaluate the cost-effectiveness of these interventions.
To evaluate specifically the cost-effectiveness of various interventions against AMI, direct cost
estimates of AMI are required [3-5]. Surprisingly, however, these cost estimates have not been
comprehensively examined in the U.S. Many studies have investigated the economic burden
of AMI, but all had some limitations [6-17]. Furthermore, in part because of limitations in avail‐
able studies, the costs of coronary heart disease (CHD) were used in one study to represent the
costs for AMI [6], albeit this is inappropriate. For example, a previous study of insured adults
aged 18-64 years found that only about 30% of CHD cases represented AMI [9]. Moreover, the
American Heart Association recently estimated that the total prevalence of CHD among per‐
sons aged ≥20 years was 7% but the AMI prevalence of AMI in this group was 3.1% [2]. In addi‐
tion, in 2005, hospitalization costs for AMI admissions among adults aged 18-64 years were
about $5000 more than those for CHD admissions of non-AMI [9]. Clearly, information on
costs that does not clearly distinguish between AMI and non-AMI admissions is of little use in
evaluating the cost-effectiveness of interventions to treat AMI [18].
© 2013 Wang et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In the present study we estimated AMI-specific costs by exploring the hospitalization costs
of AMI while incorporating the impacts on costs of percutaneous coronary intervention
(PCI), coronary artery bypass graft (CABG) surgery, comorbidities, complications, ST-eleva‐
tion status, and length of stay (LOS) while controlling for age, sex, geographic regions, and
urban versus non-urban location. Because PCI, CABG surgery, and LOS are likely to be the
most influential factors on the costs and relevant factors for evaluating cost-effectiveness of
AMI interventions, we also conducted multivariate logistic regressions to identify the fac‐
tors predicting PCI, CABG surgery, and LOS.
2. Methods
2.1. Data source
The 2006-2008 MarketScan Commercial Claims and Encounter inpatient database was used for
this study; this database contains information on patients up to age 64 years from approxi‐
mately 40 privately insured employers, including state governments, with an average of near‐
ly 21 million covered lives per year. In 2006-2008 the database had more than 2.4 billion service
records representing commercially insured employees,  qualified retirees and dependents
from over 100 geographically diverse health insurance plans in all 50 U.S. states and the Dis‐
trict of Columbia. The advantages of using the MarketScan database for economic studies in‐
clude the large sample, detailed diagnosis codes for medical services, and hospitalization costs
that are based on payment to providers [19]. Many researchers have used the MarketScan data‐
base to investigate medical costs associated with cardiovascular disease [9, 20, 21]
Using the International Classification of Diseases, 9th revision (ICD-9) codes, we identified
hospitalizations with a primary diagnosis of AMI among patients aged 18-64 years who
were enrolled in non-capitated health insurance plans. We further separated the hospitaliza‐
tions into ST-elevated myocardial infarction (STEMI) and non-ST-elevated myocardial in‐
farction (NSTEMI) cases. Based on secondary diagnosis codes, we identified major
comorbidities, complications, and procedures for these hospitalizations (Table 1).
We excluded patients younger than 18 years because AMI is very uncommon in that group.
We did not include patients in capitated health insurance plans because their costs of hospital‐
ization would not reflect the medical services provided to them. We excluded hospitalizations
with a LOS greater than 30 days because we determined that these hospitalizations (n=131, fig‐
ure 1) would skew our results. To further limit the influence of extreme values on the cost esti‐
mates, we excluded all hospitalizations with a cost in the lowest or highest 1% of values (Figure
1). The costs in our study included all those for physician services, diagnostic tests, therapeu‐
tics, supplies, and room fees during the hospitalizations. These costs, as noted above, repre‐
sented total payment to providers rather than hospital charges. Accordingly, we did not need
to adjust charges into payments to reflect the true economic burden of hospitalizations, nor did
we use unit cost per bed day or an expert panel’s suggested cost as in many other studies [5, 11,
7, 22, 23]. We expressed the costs in 2008 dollars by adjusting the 2006 and 2007 value by the
consumer price index (CPI) provided by the Bureau of Labor Statistics [24].
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AMI, comorbidity, complication, or
procedure
ICD-9 or CPT-4 code
AMI
STEMI
NSTEMI
410.xx
410.01, 410.11. 410.21. 410.31
410.71
Congestive heart failure 402.01, 402.11, 402.91, 404.01, 404.03,404.11, 404.13, 404.91,
404.93,428.xx
Hypertension 401.xx-405.xx
Diabetes 250.xx
Hyperlipidemia 272.xx
Kidney disease 403.xx, 404.xx, 582.xx, 583.xx, 585.xx, 586.xx, 587.xx
Stroke 430.xx-438.xx
Cardiogenic shock 785.51
Ventricular tachycardia 427.1
Ventricular fibrillation 427.41, 427.42
Atrial tachycardia 427.0
Atrial fibrillation 427.31, 427.32
PCI 92980-92982, 92984, 92995, 92996, 00.66, 36.01-36.09
CABG surgery 33510-33519, 33521-33523, 33533-33536, 36.10-36.19
AMI: Acute myocardial infarction.
ICD-9: International classification of disease, 9th revision.
CPT-4: Current procedural terminology, 4th revision.
STEMI: ST-elevated myocardial infarction.
NSTEMI: Non-ST-elevated myocardial infarction.
PCI: Percutaneous coronary intervention.
CABG: Coronary artery bypass graft.
Table 1. Diagnostic codes for acute myocardial infarction (AMI) and selected comorbidities and procedures
2.2. Statistical analysis
After deriving the sample means of the costs for different population groups, AMI types, co‐
morbidities, complications, and procedures, we specified various versions of multivariate re‐
gression  models  to  examine  the  factors  influencing  the  costs  while  controlling  for
demographic variables and Charlson comorbidity index (CCI) [25]. We used CCI as a compre‐
hensive measure of disease severity. It measures the likelihood of death or serious disability in
the subsequent year by diagnosis codes of up to 18 different diseases. In addition to estimating
the various versions of regression for the whole study sample, we ran a regression on the costs
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for STEMI and NSTEMI patients separately. Because PCI, CABG surgery and LOS were major
factors determining the costs, we used logistic regression to investigate the predictors of these
three factors. For the regression estimation, we used mixed-effects models with a repeated
measures approach to account for the fact that a single patient might have multiple admis‐
sions during the 3-year period. All tests of statistical significance were 2-tailed, and a p<0.001
was considered significant. All statistical analyses were performed using SAS version 9.1 [26].
 
 Total hospitalizations: 49,829 
Age ≥18 years: 49,817 
Non-capitated insurance plan: 
42,522 
Age<18 years: 12 
Capitated insurance plan: 
7295
Length of stay >30 days: 131 
Length of stay ≤30 days: 
42,391 
Cost <1% or >99%: 845 
Study sample: 41,546 
NSTEMI:  
22,567 
STEMI:  
18,979 
Figure 1. Diagram showing how the study sample was selected from all patients with a primary diagnosis of AMI in
the 2006-2008 MarketScan Commercial Claims and Encounters inpatient database. STEMI: ST-elevated myocardial in‐
farction. NSTEMI: non-ST-elevated myocardial infarction.
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N Mean costs (± SD)
Total sample 41,546 29,840.2 ± 22,900.6
Age group (year)
18-44 4671 27,537.1 ± 20,693.3
45-54 13,991 29,661.7 ± 22,073.7
55-64 22,884 30,419.4 ± 23,778.6
Sex
Female 10,874 27,102.7 ± 22,110.1
Male 30,672 30,810.7 ± 23,096.9
MSA
Yes 31,511 29,639.3 ± 22,661.9
No 10,035 30,471.0 ± 23,624.5
Region
Northeast 3296 27,623.5 ± 22,012.1
North Central 13,051 29,452.9 ± 21,927.1
South 20,992 29, 637.4 ± 23,020.8
West 4207 33,790.2 ± 25,373.3
AMI type
STEMI 18,979 32,030.3 ± 22,282.8
NSTEMI 22,567 27,998.3 ± 23,248.8
Hypertension
Yes 16,020 29,403.5 ± 21,868.0
No 25,526 30,114.3 ± 23,521.8
Congestive Heart Failure
Yes 4813 36,758.5 ± 29,163.4
No 36,733 28,933.7 ± 21,786.3
Cancer
Yes 551 29,024.5 ± 23,356.1
No 40,995 29,851.2 ± 22,894.5
Hyperlipidemia
Yes 14,075 29,375.3 ± 20,655.4
No 27,471 30,078.4 ± 23,966.5
Peripheral vascular disease
Yes 296 34,324.6 ± 26,393.2
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N Mean costs (± SD)
No 41,250 29,808.0 ± 22,870.8
Diabetes
Yes 7367 31,917.7 ± 24,735.0
No 34,179 29,392.4 ± 22,460.8
Obesity
Yes 2944 28,862.3 ± 21,845.5
No 38,602 29,914.8 ± 22,977.6
Stroke
Yes 1739 42,133.5 ± 30,090.3
No 39,807 29,303.2 ± 22,381.4
Kidney disease
Yes 1584 33,499.2 ± 27,595.5
No 39,962 29,695.2 ± 22,682.8
PCI
Yes 27,062 30,960.8 ± 19,564.6
No 14,484 27,746.5 ± 27,972.1
CABG
Yes 3879 63,105.9 ± 26,886.0
No 37,667 26,414.5 ± 19,450.5
Cardiogenic shock
Yes 1135 53,016.1 ± 32,754.6
No 40,411 29,189.3 ± 22,216.0
Ventricular tachycardia
Yes 2170 37,306.5 ± 27,619.9
No 39,376 29,428.7 ± 22,540.5
Atrial tachycardia
Yes 299 29,365.2 ± 25,149.5
No 41,247 29,843.6 ± 22,883.8
Ventricular fibrillation
Yes 1286 43,165.1 ± 29,468.8
No 40,260 29,414.6 ± 22,530.4
Atrial fibrillation
Yes 1975 38,109.7 ± 28,974.3
Ischemic Heart Disease82
N Mean costs (± SD)
No 39,571 29,427.5 ± 22,475.5
Charlson comorbidity index 41,456 1.55 ± 1.39
Length of stay (days) 41,456 4.66 ± 3.16
MSA: Metropolitan statistical area (resided in).
AMI: Acute myocardial infarction.
STEMI: ST-elevated myocardial infarction.
NSTEMI: Non-ST-elevated myocardial infarction.
PCI: Percutaneous coronary intervention.
CABG: Coronary artery bypass graft.
Table 2. Sample characteristics and mean costs (ages 18-64 years), 2006-2008 MarketScan inpatient database
3. Results
During 2006-2008, there were 41,546 hospitalizations with a primary diagnosis of AMI; their
mean cost was $29,840 (± 22,901) (Table 2). Mean cost increased with age, but just marginal‐
ly. Male patients cost more than female patients ($30,811 vs. $27,103, p<0.001), and the cost
of STEMI exceeded that of NSTEMI ($32,030 vs. 27,998, p<0.001). Major comorbidities that
increased the cost were stroke, heart failure, peripheral vascular disease, kidney disease, and
diabetes. All of the complications except atrial tachycardia increased the cost greatly. Hospi‐
talizations in which CABG surgery was performed cost a mean of $63,106, more than twice
as high as the mean of $26,415 for those without CABG surgery. PCI increased the cost mar‐
ginally.
The regression results indicated that age influenced the cost marginally after controlling for
procedures, comorbidities, complications, LOS, and ST-elevation status, as well as other
demographic variables (Model 6, Table 3). Hospitalizations of male patients had about
$3350-$4000 higher costs than those of their female counterparts in Model 1-4, but the differ‐
ences by sex dropped to $1437 when all the procedures and complications were considered
(Model 6). The cost in the West was $5608 to $6530 higher than in any other regions in the
fully adjusted model. The cost of hospitalization for STEMI was higher than that for NSTE‐
MI, but the difference decreased from about $3776 (model 2) to $1003 with adjustment for all
of the comorbidities, LOS, procedures, and complication (Model 6). CCI increased the cost
by $2362 (Model 3), but this increase largely disappeared after adding the LOS, procedures,
and complications (Model 6). Longer LOS increased the cost by about $2941 (p<0.001) per
day (Model 6). After controlling for all other factors, PCI increased the cost by about $12,546,
and CABG surgery increased the cost by about $28,406. These two procedures were the big‐
gest factors influencing the cost of AMI hospitalizations. Complications increased the cost
by $4669 in the fully adjusted model.
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Independent variable Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 STEMI NSTEMI
Age
18-44 vs. 55-64 -2895.2
±366.3 (<.
0001)
-3068.7
±365.2
(<0.0001)
2278.4
±362.4
(<0.0001)
64.9
±307.7
(0.8329)
643.8
±282.1
(0.0225)
808.3
±281.0
(0.0040)
554.9 ±
420.3
(0.1868)
955.6
±376.9
(0.0112)
45-54 vs. 55-64 -848.5
±244.7
(0.0005)
-1024.1
±244.13
(<0.0001)
564.5
±242.1
(0.0197)
998.0
±205.6
(<0.0001)
722.3
±188.5
(0.0001)
817.3
±187.8
(<0.0001)
502.8
±283.7
(0.0763)
1069.4
±249.6
(<0.0001)
Male 3720.4
±254.5
(<0.0001)
3356.3
±254.5
(<0.0001)
3804.2
±252.4
(<0.0001)
3995.7
±213.9
(<0.0001)
1574.6
±198.0
(<0.0001)
1437.1
±197.3
(<0.0001)
1046.8
±316.9
(<0.0001)
1428.8
±250.0
(<0.0001)
MSA -829.5
±262.0
(0.0015)
-834.6
±261.1
(0.0014)
-805.1
±258.5
(0.0018)
-1060.3
±219.0
(<0.0001)
-1224.5
±201.0
(<0.0001)
-1213.0
±200.1
(<0.0001)
-1495.5
±306.2
(<0.0001)
-903.1
±263.2
(0.0006)
Region
Northeast vs. West -6009.0
± 530.3
(<0.0001)
-5843.0
±528.6
(<0.0001)
-6190.7
±523.4
(<0.0001)
-7760.0
±443.7
(<0.0001)
-6469.4
±406.9
(<0.0001)
-6529.9
±405.2
(<0.0001)
-7584.1
±603.2
(<0.0001)
-5640.7 ±
546.4
(<0.0001)
North Central vs. West -4235.0
±404.0
(<0.0001)
-4045.4
±402.8
(<0.0001)
-4349.7
±398.8
(<0.0001)
-5570.7
±338.1
(<0.0001)
-5693.6
±309.9
(<0.0001)
-5735.1
±308.6
(<0.0001)
-5444.2
±454.0
(<0.0001)
-5894.0
±420.8
(<0.0001)
South vs. West -3980.0
±385.3
(<0.0001)
-3771.9
±384.2
(<0.0001)
-4291.2
±380.7
(<0.0001)
-5985.3
±322.9
(<0.0001)
-5561.9
±296.0
(<0.0001)
-5608.2
±294.8
(<0.0001)
-5959.2
±431.8
(<0.0001)
-5266.7
±403.3
(<0.0001)
STEMI --- 3775.6
±224.8
(<0.0001)
4116.3
±222.8
(<0.0001)
3654.9
±188.9
(<0.0001)
1335.6
±182.3
(<0.0001)
1002.8
±182.4
(<0.0001)
--- ---
Charlson comorbidity
index
--- --- 2361.8
±80.3
(<0.0001)
-257.9
±71.0
(0.0003)
169.1
±65.3
(0.0085)
169.7
±65.0
(0.0091)
361.6
±11067
(0.0011)
80.9 ±79.5
(0.3091)
Length of stay --- --- --- 3974.8
±31.1
(<0.0001)
3044.0
±32.3
(<0.0001)
2940.7
±32.6
(<0.0001)
3061.7
±51.6
(<0.0001)
2865.5
± 41.8
(<0.0001)
PCI --- --- --- --- 12490.0
±204.5
(<0.0001)
12546.1
±203.7
(<0.0001)
10169.0
±366.5
(<0.0001)
13657.1
±241.1
(<0.0001)
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CABG --- --- --- --- 28189.4
±352.7
(<0.0001)
28405.6
±351.5
(<0.0001)
26476.2
±599.8
(<0.0001)
29395.9
±431.8
(<0.0001)
Complications --- --- --- --- --- 4669.1
±252.5
(<0.0001)
4803.8
±350.6
(<0.0001)
4498.8
±368.0
(<0.0001)
Model 1: Age, sex, MSA, and region;
Model 2: Model 1 + STEMI;
Model 3: Model 2 + comorbidities;
Model 4: Model 3 + length of stay;
Model 5: Model 4 + PCI, CABG surgery;
Model 6: Model 5 + complications;
MSA: Metropolitan statistical area (resided in).
STEMI: ST-elevated myocardial infarction.
NSTEMI: Non-ST-elevated myocardial infarction.
PCI: Percutaneous coronary intervention.
CABG: Coronary artery bypass graft.
Table 3. Coefficient estimates of hospitalization costs for patients with acute myocardial infarction
PCI and CABG surgery increased the cost for both the STEMI and NSTEMI groups, with
both procedures increasing the cost more for the NSTEMI group than for STEMI. LOS, in
contrast, increased the cost more for the STEMI than the NSTEMI group, while living in an
urban area (MSA in Table 3) decreased cost by $1496 for STEMI and $903 for NSTEMI.
Logistic regression indicated that patients aged 18-44 years were less likely than those aged
55-64 to undergo PCI or to have CABG surgery, and they were more likely to have a shorter
LOS (i.e., <5 days) (Table 4). Patients in urban area were more likely to have PCI, but less
likely to have CABG. Men were more likely to undergo PCI or to have CABG surgery than
were women, but their odd of a short LOS was greater. Versus patients who did not live in
urban areas, urban patients were more likely to have PCI, but they were less likely to under‐
go CABG surgery. Compared with patients in the West, patients in other regions were more
likely to have a long LOS (i.e., ≥5 days), but they were usually less likely to have PCI and
CABG surgery, with PCI in the North Central region the exception. STEMI patients were
more likely than NSTEMI patients to undergo PCI and CABG surgery, and they were more
likely to have a long LOS. Patients with comorbidities or complications were more likely to
have a long LOS, but they were less likely to have PCI or CABG surgery. Patients undergo‐
ing PCI were more likely to have a short LOS, while patients undergoing CABG surgery
were far more likely to have a long LOS.
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Independent variable PCI (yes vs. no) CABG (yes vs. no) Length of stay (<5 vs. ≥5)
Age 18-44 vs. 55-64 years 0.877 (0.814, 0.944) 0.718 (0.616, 0.836) 0.706 (0.651, 0.765)
Age 45-54 vs. 55-64 years 1.170 (1.112, 1.232) 1.010 (0.921, 1.107) 0.807 (0.767, 0.851)
Male 1.813 (1.724, 1.907) 2.776 (2.502, 3.081) 0.760 (0.721, 0.801)
MSA 1.249 (1.184, 1.317) 0.905 (0.824, 0.995) 1.044 (0.988, 1.104)
Region
Northeast vs. West 0.792 (0.711, 0.884) 0.488 (0.391, 0.608) 1.560 (1.392, 1.747)
North Central vs. West 1.153 (1.059, 1.256) 0.969 (0.830, 1.132) 1.267 (1.158, 1.387)
South vs. West 0.884 (0.815, 0.959) 0.934 (0.806, 1.081) 1.486 (1.364, 1.620)
STEMI vs. NSTEMI 4.514 (4.293, 4.746) 1.337 (1.219, 1.467) 1.333 (1.267, 1.402)
Charlson comorbidity index 0.890 (0.876, 0.905) 0.887 (0.862, 0.913) 1.432 (1.408, 1.457)
Length of stay (days) 0.981 (0.973, 0.990) 1.405 (1.388, 1.422) ---
PCI --- 0.060 (0.053, 0.067) 0.819 (0.776, 0.866)
CABG 0.062 (0.056, 0.069) --- 47.992 (41.288, 55.785)
Complications 0.894 (0.834, 0.959) 0.863 (0.771, 0.966) 2.621 (2.460, 2.793)
PCI: Percutaneous coronary intervention.
CABG: Coronary artery bypass graft.
MSA: Metropolitan statistical area (resided in).
STEMI: ST-elevated myocardial infarction.
NSTEMI: Non-ST-elevated myocardial infarction.
Table 4. Coefficient estimates of logistic regression of PCI, CABG, and length of stay
4. Discussion
The large number of hospitalizations in our economic study of inpatients who had suffered
an AMI enabled us to explore a variety of factors that influenced their costs. The results sug‐
gest that CABG and PCI are the biggest drivers of hospital costs for AMI patients, adding,
respectively, $12,546 and $28,406 to the cost of a stay. The cost effects of PCI and CABG in
our study were comparable to the $15,089 and $28,974 additional costs, respectively, found
in a Medicare population [7]. Another study reported similar costs for PCI and CABG [17].
In an earlier study using MarketScan data from 2003 to 2006, Zhao and Winget found that
the total hospitalization costs of PCI and CABG surgery patient costs were, respectively,
Ischemic Heart Disease86
$31,379 and $63,909 [10]. Unfortunately, Zhao and Winget did not explore the effects of PCI
and CABG on the costs of stay, as we did in our study. Such information is needed to evalu‐
ate the cost-effectiveness of AMI interventions [4].
Two other significant drivers of cost in our study were complications and LOS. Having one
or more complications increased the cost by over $4600, and LOS increased the cost by over
$2900 per day. LOS was highly correlated with CABG surgery and with complications, as
indicated in our logistic models (Table 4). Thus, interventions aiming to prevent or better
manage the complications of AMI patients might be cost-effective in reducing the hospitali‐
zation costs of this group.
Hospitalizations with STEMI had, on average, higher costs than NSTEMI hospitalizations,
but after including PCI and CABG surgery as well as complications, comorbidities, and LOS
in the regression model, the magnitude of the effect became much smaller. This may be be‐
cause of differences in treatment approaches and in complications between the two kinds of
hospitalizations. For example, over 80% of STEMI hospitalizations had a PCI while only
about 51% in the NSTEMI group did. However, the NSTEMI group had a higher rate of
CABG surgery than did STEMI (12% vs. 8%) (not shown in tables). On the other hand, com‐
pared with NSTEMI cases, the STEMI group had a higher rate of cardiogenic shock, ventric‐
ular tachycardia, and ventricular fibrillation, but it had a lower rate of heart failure, atrial
tachycardia, and atrial fibrillation. All of these factors would affect the cost differences be‐
tween STEMI and NSTEMI hospitalizations. The fact that STEMI cost more than NSTEMI
was consistent with the literature; in Mexico, for example, STEMI cost nearly $2800 more
than NSTEMI [11].
The predictors of PCI, CABG surgery, and LOS that we set forward in this study provide
important information for secondary cost-effectiveness analyses of AMI interventions. We
found that male patients were more likely than females to have PCI and CABG surgery, but
their odds of a shorter LOS (<5 days) were greater. STEMI status greatly increased the prob‐
ability of having PCI (coefficient estimate of 4.514) and significantly increased the probabili‐
ty of CABG surgery (coefficient estimate of 1.337), and it was associated with greater odds of
a longer LOS (≥5 days). Patients with comorbidities and complications were relatively less
likely to undergo PCI and CABG surgery, but they were more likely to have a longer LOS.
All of these results could be used as inputs in cost-effectiveness evaluations of AMI inter‐
ventions.
The numerous strengths of this study notwithstanding, several limitations should be consid‐
ered when interpreting our results. First, all of our patients were covered by non-capitated
private insurance plans. Although the costs of these patients accurately reflect the true eco‐
nomic burden imposed by their hospitalizations, the special population may have limited
the generalizability of our results to the broader U.S. population. Second, all of our patients
were 18-64 years old. The elderly population (aged >64 years) has much higher incidence
and prevalence of AMI and its related comorbidities and complications [1, 2]; as a conse‐
quence, the total costs of AMI should be higher in this population than among those 18-64.
Although many studies have focused on the cost of AMI among the elderly [4, 5, 8], new
estimation methods are needed along with high-quality data to develop better cost estimates
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for this population. Unfortunately, our data would not be appropriate for an analysis of
costs among the elderly population for AMI hospitalization. A third limitation is that we es‐
timated the costs of hospitalizations only. With survival rates increasing because of advan‐
ces in technology [1], AMI patients are living longer. Correspondingly, the lifetime costs of
outpatient care and medications for afflicted patients should be increasing. Additionally,
productivity losses from the morbidity and premature mortality associated with AMI are al‐
so high [10] and should be considered in any comprehensive economic evaluations.
Given all of these factors, the hospitalization costs presented in our report should be treated
as a conservative estimate of the economic burden associated with AMI. Moreover, we
should note the limitation that we analyzed the costs of hospitalizations with AMI as a pri‐
mary diagnosis. Although this decision let us cover the majority of AMI cases, there may be
substantial additional hospitalizations in which AMI is a secondary diagnosis [9]. These hos‐
pitalizations should certainly be included in any complete analysis of the costs of hospitali‐
zations of AMI patients. Because examining the costs of AMI as a secondary diagnosis
would require a different analytical framework from the one we used, it would have been
beyond the scope of our analysis.
5. Conclusion
Using a large set of claims data, we estimated the hospitalization costs of patients with a pri‐
mary diagnosis of AMI and identified the main cost drivers of this important problem. Be‐
cause most previous studies did not provide any information on the predictors of the costs
of AMI hospitalizations [27], we hope that the present study has to some degree filled this
gap in the literature. The high costs of AMI could be an economic justification for policy
makers to support efforts to prevent AMI. In addition, the detailed information presented
herein about the impact of various factors on the costs, procedures, and LOS associated with
hospitalizations having a primary diagnosis of AMI can be used to evaluate and support
health economic research such as studies on the cost-effectiveness of interventions to control
this problem.
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